Creatine Monohydrate ( DrugBank: Creatine )

---

4 diseases

ID	Disease name (Link within this page)	Number of trials
2	Amyotrophic lateral sclerosis	2
8	Huntington disease	5
113	Muscular dystrophy	2
156	Rett syndrome	1

2. Amyotrophic lateral sclerosis

---

Clinical trials : 645 /  Drugs : 589 - (DrugBank : 163) / Drug target genes : 150 - Drug target pathways : 225

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00069186 (ClinicalTrials.gov)	June 2003	17/9/2003	Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis	A Phase III, Multi-Center, Double-Blind, Placebo Controlled, Randomized Study of Creatine Monohydrate in Patients With Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis (ALS)	Drug: Creatine Monohydrate	The Avicena Group	NULL	Active, not recruiting	21 Years	80 Years	Both	107	Phase 3	United States
2	NCT00070993 (ClinicalTrials.gov)	December 2002	9/10/2003	Creatine for the Treatment of Amyotrophic Lateral Sclerosis	Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis	Amyotrophic Lateral Sclerosis	Drug: creatine monohydrate	National Center for Complementary and Integrative Health (NCCIH)	Office of Dietary Supplements (ODS)	Completed	21 Years	80 Years	Both	110	Phase 2	United States

8. Huntington disease

---

Clinical trials : 242 /  Drugs : 205 - (DrugBank : 62) / Drug target genes : 85 - Drug target pathways : 159

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01411163 (ClinicalTrials.gov)	April 2010	4/8/2011	Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability	Premanifest Huntington's Disease Extension Study II: Creatine Safety & Tolerability	Huntington's Disease	Drug: Creatine monohydrate	Massachusetts General Hospital	National Institutes of Health (NIH)	Completed	26 Years	N/A	Both	24	Phase 2	United States
2	NCT00712426 (ClinicalTrials.gov)	September 2009	8/7/2008	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Creatine Safety, Tolerability, & Efficacy in Huntington's Disease (CREST-E)	Huntington's Disease	Drug: Creatine Monohydrate;Drug: Placebo	Massachusetts General Hospital	University of Rochester;National Center for Complementary and Integrative Health (NCCIH)	Terminated	18 Years	N/A	Both	553	Phase 3	United States;Australia;Canada;New Zealand
3	NCT01411150 (ClinicalTrials.gov)	May 2009	4/8/2011	Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study	Premanifest Huntington's Disease: Creatine Safety & Tolerability Extension Study	Huntington's Disease	Drug: Creatine Monohydrate	Massachusetts General Hospital	National Institutes of Health (NIH)	Completed	26 Years	N/A	Both	38	Phase 2	United States
4	NCT00592995 (ClinicalTrials.gov)	December 2007	28/12/2007	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Creatine Safety and Tolerability in Premanifest HD: PRECREST	Huntington Disease	Drug: Creatine monohydrate;Drug: Placebo	Massachusetts General Hospital	NULL	Completed	26 Years	N/A	Both	64	Phase 2	United States
5	NCT01412151 (ClinicalTrials.gov)	April 2005	5/8/2011	Creatine Safety & Tolerability in Huntington's Disease	Creatine Safety & Tolerability in Huntington's Disease (CREST-X): A Single-Center, Open-Label, Long-Term Safety & Tolerability Extension Study of Creatine in Subjects With HD	Huntington's Disease (HD)	Drug: Creatine monohydrate	Massachusetts General Hospital	NULL	Completed	18 Years	N/A	All	10	Phase 2	United States

Back to top

113. Muscular dystrophy

---

Clinical trials : 646 /  Drugs : 471 - (DrugBank : 105) / Drug target genes : 59 - Drug target pathways : 170

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT00018109 (ClinicalTrials.gov)	June 2001	3/7/2001	A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)	A Multicenter Randomized Placebo-Controlled Double-Blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy (DMD)	Muscular Dystrophy, Duchenne	Drug: glutamine;Drug: creatine monohydrate	National Center for Research Resources (NCRR)	Children's Research Institute	Completed	5 Years	10 Years	Male		Phase 3	United States
2	NCT00016653 (ClinicalTrials.gov)	June 2000	21/5/2001	Creatine and Glutamine in Steroid-Naive Duchenne Muscular Dystrophy	A Multicenter Randomized Placebo-controlled Double-blind Study to Assess Efficacy and Safety of Glutamine and Creatine Monohydrate in Duchenne Muscular Dystrophy	Muscular Dystrophy, Duchenne	Drug: Creatine Monohydrate;Drug: Glutamine	Cooperative International Neuromuscular Research Group	NULL	Completed	5 Years	9 Years	Male	48	Phase 2/Phase 3	United States;Belgium;Israel;Puerto Rico

156. Rett syndrome

---

Clinical trials : 44 /  Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01147575 (ClinicalTrials.gov)	January 2005	17/6/2010	Effects of Creatine Supplementation in Rett Syndrome	Effects of Creatine Supplementation in Rett Syndrome: A Randomized, Placebo-controlled Trial	Rett Syndrome	Dietary Supplement: Creatine monohydrate;Dietary Supplement: Placebo	Medical University of Vienna	NULL	Completed	3 Years	24 Years	Female	21	N/A	Austria

Back to top